MoneyWorks4Me

Hikal gets nod to raise Rs 375 crore through NCDs

14 Feb 2022 Evaluate

Hikal has received approval to raise Rs 375 crore through 3750 Unrated, unlisted, secured, redeemable, Non-Convertible Debentures (NCDs) on private placement basis. Date of maturity will be 8 years from the date of allotment. The Board of Directors of the Company at its meeting held on February 14, 2022, has approved the same.

Hikal is a leading manufacturer and supplier of API's and intermediates globally.

Peers
Company Name CMP
Sun Pharma. Inds. 1853.50
Dr. Reddys Labs. 1202.80
Cipla 1397.20
Lupin 2090.00
Zydus Lifesciences 1202.00
View more..